Quick Answer
Bioventus Inc. reported Total Revenue of $568.09 million for fiscal year 2025.
Bioventus Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $568.09M -0.9% |
$573.28M +11.9% |
$512.35M +0.0% |
$512.12M +18.8% |
$430.90M +34.2% |
$321.16M -5.6% |
| Revenue (ASC 606) | $568.09M -0.9% |
$573.28M +11.9% |
$512.35M +0.0% |
$512.12M +18.8% |
$430.90M +34.2% |
$321.16M -5.6% |
| Net Income | $22.73M +162.9% |
-$36.12M +76.9% |
-$156.23M +1.6% |
-$158.70M -919.1% |
$19.38M +18.1% |
$16.41M +139.5% |
| Diluted EPS | $0.33 +158.9% |
-$0.56 +77.5% |
-$2.49 +3.9% |
-$2.59 -1626.7% |
-$0.15 | — |
| Total Assets | $683.56M -6.1% |
$727.96M -10.2% |
$810.91M -40.9% |
$1.37B +12.0% |
$1.23B +147.9% |
$494.47M |
| Cash and Equivalents | $51.24M +23.2% |
$41.58M +12.5% |
$36.96M +22.5% |
$30.19M -31.3% |
$43.93M -49.4% |
$86.84M |
| Long-Term Debt | $278.95M -9.5% |
$308.29M -16.0% |
$367.00M -4.7% |
$385.01M +13.4% |
$339.64M +95.9% |
$173.38M |
| Stockholders Equity | $184.10M +24.4% |
$147.94M -14.8% |
$173.59M -46.6% |
$325.24M -29.1% |
$458.92M | — |
| R&D Expense | $12.11M -13.2% |
$13.95M +3.8% |
$13.45M -43.6% |
$23.85M +25.3% |
$19.04M +70.0% |
$11.20M +1.3% |
| Operating Income | $53.98M +455.2% |
-$15.20M +81.4% |
-$81.72M +51.1% |
-$167.23M -1486.6% |
$12.06M -43.2% |
$21.24M -31.9% |
| Gross Profit | $388.16M -0.0% |
$388.23M +18.3% |
$328.19M -0.9% |
$331.08M +9.4% |
$302.71M +29.6% |
$233.52M -6.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $138.65M | -0.2% | -6.1% |
| Revenue (ASC 606) | September 30, 2025 | $138.65M | -0.2% | -6.1% |
| Net Income | September 30, 2025 | $3.15M | +161.1% | -57.7% |
| Diluted EPS | September 30, 2025 | $0.05 | +162.5% | -54.5% |
| Total Assets | September 30, 2025 | $701.59M | -8.8% | -0.7% |
| Cash and Equivalents | September 30, 2025 | $42.16M | -2.1% | +28.1% |
| Long-Term Debt | September 30, 2025 | $311.33M | -9.8% | +4.5% |
| Stockholders Equity | September 30, 2025 | $166.10M | +11.7% | +3.0% |
| R&D Expense | September 30, 2025 | $2.92M | -23.9% | -7.8% |
| Operating Income | September 30, 2025 | $11.25M | +208.5% | -38.7% |
| Gross Profit | September 30, 2025 | $94.23M | +0.7% | -7.7% |
- Bioventus Inc. reported Total Revenue of $568.09 million for fiscal year 2025.
- Bioventus Inc. showed a decrease of -0.9% in Total Revenue compared to the prior fiscal year.
- Bioventus Inc. reported Revenue (ASC 606) of $568.09 million for fiscal year 2025.
- Bioventus Inc. showed a decrease of -0.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Bioventus Inc. reported Net Income of $22.73 million for fiscal year 2025.
- Bioventus Inc. showed an increase of +162.9% in Net Income compared to the prior fiscal year.
- Bioventus Inc. reported Diluted EPS of $0.33 per share for fiscal year 2025.
- Bioventus Inc. showed an increase of +158.9% in Diluted EPS compared to the prior fiscal year.
- Bioventus Inc. reported Total Assets of $683.56 million for fiscal year 2025.
- Bioventus Inc. showed a decrease of -6.1% in Total Assets compared to the prior fiscal year.
- Bioventus Inc. reported Cash and Equivalents of $51.24 million for fiscal year 2025.
- Bioventus Inc. showed an increase of +23.2% in Cash and Equivalents compared to the prior fiscal year.
- Bioventus Inc. reported Long-Term Debt of $278.95 million for fiscal year 2025.
- Bioventus Inc. showed a decrease of -9.5% in Long-Term Debt compared to the prior fiscal year.
- Bioventus Inc. reported Stockholders Equity of $184.10 million for fiscal year 2025.
- Bioventus Inc. showed an increase of +24.4% in Stockholders Equity compared to the prior fiscal year.
- Bioventus Inc. reported R&D Expense of $12.11 million for fiscal year 2025.
- Bioventus Inc. showed a decrease of -13.2% in R&D Expense compared to the prior fiscal year.
- Bioventus Inc. reported Operating Income of $53.98 million for fiscal year 2025.
- Bioventus Inc. showed an increase of +455.2% in Operating Income compared to the prior fiscal year.
- Bioventus Inc. reported Gross Profit of $388.16 million for fiscal year 2025.
- Bioventus Inc. showed a decrease of -0.0% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: